Physicians

Departments / Divisions

• Pediatrics / Pediatrics-Hematology/Oncology
• Surgery / Neurosurgery

Address
DUMC 102382
Durham, NC 27710

Appointment Telephone
919-668-6288

Office Telephone
919-668-6288

Fax Telephone
919-668-2485

Training

• MRCP (UK), Stanley Medical College (India), 1982

Residency

• Pediatrics, Le Bonheur Children's Medical Center (Tennessee), 1992-1993

Fellowship

• Pediatric Hematology-Oncology, Saint Jude Children's Research Hospital (Tennessee), 1991-1992
• Pediatric Hematology-Oncology, Memorial Sloan-Kettering Cancer Center (New York), 1996-1999

Other Training

• Member (Pediatrics), Royal College of Physicians (UK), 1988

Clinical Interests
Developing innovative phase 1 and 2 trials in the treatment of children with recurrent brain tumors

Research Interests
Dr. Gururangan is a member of the Duke University Medical Center Pediatric Neuro-Oncology program. His current research interest focuses on finding novel chemotherapeutic strategies for the treatment of children and young adults with brain tumors. Since beginning his tenure at the Brain Tumor Center at Duke, he has written seven clinical protocols. These protocols have incorporated some of the important laboratory findings obtained from the laboratory of Dr. Henry Friedman. These protocols are designed to improve survival of children and young adults with brain stem gliomas and other malignant brain tumors. These protocols will be administered locally and in other prominent brain tumor centers around the country that are part of the Pediatric Brain Tumor Consortium. Dr. Gururangan is the subsite principal investigator for another multi-institutional phase III study of upfront radiation therapy followed dose intensive chemotherapy plus stem cell rescue in children with newly diagnosed medulloblastoma, other PNETs, and ATRT. This study originates at St. Jude Children's Research Hospital, Memphis, TN. The Preston Robert Tisch Brain Tumor Center also has a broad-based agreement with the same institution for broad-based collaboration for clinical trials that originate at Duke or St. Jude Children's Hospital. Dr. Gururangan is the Principal Investigator for Duke in the Pediatric Brain Tumor Consortium sponsored by the National Cancer Institute. He has completed and published two phase I studies through this consortium involving novel alkylating agents in children with recurrent brain tumors. He is currently the chair of an ongoing large phase II study of Bevacizumab plus irinotecan in children with recurrent malignant glioma, diffuse brain stem glioma, medulloblastoma, ependymoma, and low grade gliomas that is also managed through the consortium. Dr. Gururangan is a member of the Duke Brain Tumor SPORE program and the Children's Oncology Group. Also, through his close ties with an elite group of basic and translational scientists at Duke, he is involved in developing immunology based therapies for children with brain tumors. As a member of these mutliple intramural and extramural groups he is in a strategic position to evaluate novel therapeutic modalities in patients with brain tumors and conduct other phase I and II clinical trials in children with brain tumors.

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Fouladi, M; Stewart, CF; Olson, J; Wagner, LM; Onar-Thomas, A; Kocak, M; Packer, RJ; Goldman, S; Gururangan, S; Gajjar, A; Demuth, T; Kun, LE; Boyett, JM; Gilbertson, RJ. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology. 2011;29:3529-3534. (2011) Abstract

Peters, KB; Cummings, TJ; Gururangan, S. Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. Journal of Pediatric Hematology/Oncology. 2011;33:e198-e201. (2011) Abstract

Rajagopal, MU; Hathout, Y; MacDonald, TJ; Kieran, MW; Gururangan, S; Blaney, SM; Phillips, P; Packer, R; Gordish-Dressman, H; Rood, BR. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011;11:935-943. (2011) Abstract

Dunkel, IJ; Jubran, RF; Gururangan, S; Chantada, GL; Finlay, JL; Goldman, S; Khakoo, Y; O'Brien, JM; Orjuela, M; Rodriguez-Galindo, C; Souweidane, MM; Abramson, DH. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatric Blood and Cancer. 2010;54:384-387. (2010) Abstract

Fangusaro, J; Massimino, M; Rutkowski, S; Gururangan, S. Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents. Pediatric Blood and Cancer. 2010;54:638-640. (2010) Abstract

Geyer, JR; Stewart, CF; Kocak, M; Broniscer, A; Phillips, P; Douglas, JG; Blaney, SM; Packer, RJ; Gururangan, S; Banerjee, A; Kieran, MW; Kun, LE; Gilbertson, RJ; Boyett, JM. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. European Journal of Cancer. 2010;46:3287-3293. (2010) Abstract

Gururangan, S; Chi, SN; Young Poussaint, T; Onar-Thomas, A; Gilbertson, RJ; Vajapeyam, S; Friedman, HS; Packer, RJ; Rood, BN; Boyett, JM; Kun, LE. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. Journal of Clinical Oncology. 2010;28:3069-3075. (2010) Abstract

Fouladi, M; Gururangan, S; Moghrabi, A; Phillips, P; Gronewold, L; Wallace, D; Sanford, RA; Gajjar, A; Kun, LE; Heideman, R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009;115:3243-3253. (2009) Abstract

Gururangan, S. Late effects of chemotherapy. Cancer Treatment and Research. 2009;150:43-65. (2009) Abstract

Bonner, MJ; Hardy, KK; Willard, VW; Anthony, KK; Hood, M; Gururangan, S. Social functioning and facial expression recognition in survivors of pediatric brain tumors. Journal of Pediatric Psychology. 2008;33:1142-1152. (2008) Abstract

Fouladi, M; Chintagumpala, M; Ashley, D; Kellie, S; Gururangan, S; Hassall, T; Gronewold, L; Stewart, CF; Wallace, D; Broniscer, A; Hale, GA; Kasow, KA; Merchant, TE; Morris, B; Krasin, M; Kun, LE; Boyett, JM; Gajjar, A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. Journal of Clinical Oncology. 2008;26:3749-3755. (2008) Abstract

Gururangan, S; Frankel, W; Broaddus, R; Clendenning, M; Senter, L; McDonald, M; Eastwood, J; Reardon, D; Vredenburgh, J; Quinn, J; Friedman, HS. Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro-Oncology. 2008;10:93-97. (2008) Abstract

Gururangan, S; Krauser, J; Watral, MA; Driscoll, T; Larrier, N; Reardon, DA; Rich, JN; Quinn, JA; Vredenburgh, JJ; Desjardins, A; McLendon, RE; Fuchs, H; Kurtzberg, J; Friedman, HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology. 2008;10:745-751. (2008) Abstract

Gururangan, S; Turner, CD; Stewart, CF; O'Shaughnessy, M; Kocak, M; Poussaint, TY; Phillips, PC; Goldman, S; Packer, R; Pollack, IF; Blaney, SM; Karsten, V; Gerson, SL; Boyett, JM; Friedman, HS; Kun, LE. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clinical Cancer Research. 2008;14:1124-1130. (2008) Abstract

Hardy, KK; Bonner, MJ; Willard, VW; Watral, MA; Gururangan, S. Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. 2008;17:1157-1161. (2008) Abstract

Keir, ST; Morton, CL; Billups, C; Smith, MA; Houghton, PJ; Gururangan, S. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatric Blood and Cancer. 2008;51:439-441. (2008) Abstract

Serafini, S; Gururangan, S; Friedman, A; Haglund, M. Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. Journal of Neurosurgery: Pediatrics. 2008;1:247-254. (2008) Abstract

Walker, JA; Dixon, N; Gururangan, S; Thornburg, C. Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B. Haemophilia. 2008;14:387-389. (2008) Abstract

Bai, F; Minkin, P; Fraga, CH; O'Shaughnessy, MA; Gururangan, S; Stewart, CF. Determination of Cloretazine (VNP40101M) and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2007;853:97-104. (2007) Abstract

Boruchov, DM; Gururangan, S; Driscoll, MC; Bussel, JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110:3526-3531. (2007) Abstract

Broniscer, A; Gururangan, S; MacDonald, TJ; Goldman, S; Packer, RJ; Stewart, CF; Wallace, D; Danks, MK; Friedman, HS; Poussaint, TY; Kun, LE; Boyett, JM; Gajjar, A. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clinical Cancer Research. 2007;13:6712-6718. (2007) Abstract

Gururangan, S. Advances in the diagnosis and treatment of malignant childhood brain tumors. Clinical Advances in Hematology and Oncology. 2007;5:120-122. (2007) Abstract

Gururangan, S; Fisher, MJ; Allen, JC; Herndon, JE; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Desjardins, A; Phillips, PC; Watral, MA; Krauser, JM; Friedman, AH; Friedman, HS. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology. 2007;9:161-168. (2007) Abstract

Jackson, EM; Shaikh, TH; Gururangan, S; Jones, MC; Malkin, D; Nikkel, SM; Zuppan, CW; Wainwright, LM; Zhang, F; Biegel, JA. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Human Genetics. 2007;122:117-127. (2007) Abstract

Kieran, MW; Packer, RJ; Onar, A; Blaney, SM; Phillips, P; Pollack, IF; Geyer, JR; Gururangan, S; Banerjee, A; Goldman, S; Turner, CD; Belasco, JB; Broniscer, A; Zhu, Y; Frank, E; Kirschmeier, P; Statkevich, P; Yver, A; Boyett, JM; Kun, LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology. 2007;25:3137-3143. (2007) Abstract

Gururangan, S; McLaughlin, CA; Brashears, J; Watral, MA; Provenzale, J; Coleman, RE; Halperin, EC; Quinn, J; Reardon, D; Vredenburgh, J; Friedman, A; Friedman, HS. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. Journal of Neuro-Oncology. 2006;77:207-212. (2006) Abstract

Gururangan, S; Petros, WP; Poussaint, TY; Hancock, ML; Phillips, PC; Friedman, HS; Bomgaars, L; Blaney, SM; Kun, LE; Boyett, JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clinical Cancer Research. 2006;12:1540-1546. (2006) Abstract

Pekala, JS; Gururangan, S; Provenzale, JM; Mukundan, S. Central nervous system extraosseous Ewing sarcoma: radiologic manifestations of this newly defined pathologic entity. American Journal of Neuroradiology. 2006;27:580-583. (2006) Abstract

Mazur, MA; Gururangan, S; Bridge, JA; Cummings, TJ; Mukundan, S; Fuchs, H; Larrier, N; Halperin, EC. Intracranial Ewing sarcoma. Pediatric Blood and Cancer. 2005;45:850-856. (2005) Abstract

Gururangan, S; Friedman, HS. Recent advances in the treatment of pediatric brain tumors. Oncology. 2004;18:1649-1661. (2004) Abstract

Gururangan, S; Hwang, E; Herndon, JE; Fuchs, H; George, T; Coleman, RE. [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55:1280-1288. (2004) Abstract

Mulhern, RK; Khan, RB; Kaplan, S; Helton, S; Christensen, R; Bonner, M; Brown, R; Xiong, X; Wu, S; Gururangan, S; Reddick, WE. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. Journal of Clinical Oncology. 2004;22:4795-4803. (2004) Abstract

Provenzale, JM; Gururangan, S; Klintworth, G. Trilateral retinoblastoma: clinical and radiologic progression. American Journal of Roentgenology. 2004;183:505-511. (2004) Abstract

Gururangan, S; McLaughlin, C; Quinn, J; Rich, J; Reardon, D; Halperin, EC; Herndon, J; Fuchs, H; George, T; Provenzale, J; Watral, M; McLendon, RE; Friedman, A; Friedman, HS; Kurtzberg, J; Vredenbergh, J; Martin, PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology. 2003;21:2187-2191. (2003) Abstract

Gururangan, S; Cavazos, CM; Ashley, D; Herndon, JE; Bruggers, CS; Moghrabi, A; Scarcella, DL; Watral, M; Tourt-Uhlig, S; Reardon, D; Friedman, HS. Phase II study of carboplatin in children with progressive low-grade gliomas. Journal of Clinical Oncology. 2002;20:2951-2958. (2002) Abstract

Gururangan, S; Friedman, HS. Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clinics of North America. 2002;12:583-597. (2002) Abstract

Turner, CD; Gururangan, S; Eastwood, J; Bottom, K; Watral, M; Beason, R; McLendon, RE; Friedman, AH; Tourt-Uhlig, S; Miller, LL; Friedman, HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology. 2002;4:102-108. (2002) Abstract

Gururangan, S; Cokgor, L; Rich, JN; Edwards, S; Affronti, ML; Quinn, JA; Herndon, JE; Provenzale, JM; McLendon, RE; Tourt-Uhlig, S; Sampson, JH; Stafford-Fox, V; Zaknoen, S; Early, M; Friedman, AH; Friedman, HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 2001;3:246-250. (2001) Abstract

Gururangan, S; Sposto, R; Cairo, MS; Meadows, AT; Finlay, JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. Journal of Clinical Oncology. 2000;18:2017-2025. (2000) Abstract

Gururangan, S; Marina, NM; Luo, X; Parham, DM; Tzen, CY; Greenwald, CA; Rao, BN; Kun, LE; Meyer, WH. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. Journal of Pediatric Hematology/Oncology. 1998;20:55-61. (1998) Abstract

Gururangan, S; McFarland, JG; Cines, DB; Skupski, D; Bussel, JB. BRa (HPA-5b) incompatibility may cause thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology. 1998;20:202-206. (1998) Abstract

Gururangan, S; Heideman, RL; Kovnar, EH; Sanford, RA; Kun, LE. Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts. Pediatric Blood and Cancer. 1994;22:417-420. (1994) Abstract

Gururangan, S; Bowman, LC; Parham, DM; Wilimas, JA; Rao, B; Pratt, CB; Douglass, EC. Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide. Cancer. 1993;71:2653-2659. (1993) Abstract